Method for treating pervasive development disorders

• US 9,624,526 B2
• Filed: 12/07/2011
• Issued: 04/18/2017
• Est. Priority Date: 12/17/1999
• Status: Expired due to Fees

• Current Assignee: Curemark LLC
• Original Assignee: Curemark LLC
• Inventors: Fallon, Joan M.
• Primary Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US13/313,708
• Publication Number:
  US 20120114626A1
• Time in Patent Office: 1,959 Days
• CPC Class Codes: A61B 5/1118 Determining activity level
• CPC Class Codes: A61B 5/16 Devices for psychotechnics using teaching or educational appliances G09B1/00 - G09B7/00; Testing reaction times ; Devices for evaluating the psychological state
• CPC Class Codes: A61B 5/165 Evaluating the state of mind, e.g. depression, anxiety
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61K 38/2235 Secretins
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 38/48 acting on peptide bonds (3.4)
• CPC Class Codes: A61K 38/4826 Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C12Q 1/37 involving peptidase or proteinase
• CPC Class Codes: C12Y 302/0102 Alpha-glucosidase (3.2.1.20)
• CPC Class Codes: C12Y 304/21001 Chymotrypsin (3.4.21.1)
• CPC Class Codes: C12Y 304/21004 Trypsin (3.4.21.4)
• CPC Class Codes: G01N 2333/976 Trypsin; Chymotrypsin
• CPC Class Codes: Y10S 435/803 Physical recovery methods, e.g. chromatography, grinding
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. A method for determining the efficacy of neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with neuropeptides, peptides, or digestive enzyme administration.

Claims

1. A method for treating an individual having an autistic disorder, the method comprising measuring a level of fecal chymotrypsin in a sample from the individual and administering to the individual three or more doses per day of an effective amount of digestive enzymes if the individual has a subnormal level of fecal chymotrypsin to promote changes in autistic behavior by ameliorating a symptom of the autistic disorder, wherein the digestive enzymes comprise a protease, an amylase and a lipase.

2. The method of claim 1, wherein the symptom comprises an impairment in making eye contact with another individual.

3. The method of claim 1, wherein the symptom comprises a lack of social interaction.

4. The method of claim 1, wherein the symptom comprises a delay in, or lack of, spoken language.

5. The method of claim 1, wherein the symptom comprises a repetitive pattern of behavior such as arm flapping.

6. The method of claim 1, wherein the symptom comprises hyperactivity.

7. The method of claim 1, wherein the symptom comprises a lack of a formed bowel movement.

8. The method of claim 1, wherein the symptom comprises a lack of toilet training.

9. The method of claim 1, wherein the method comprises administering digestive enzymes comprising approximately 4,000 to approximately 60,000 United States Pharmacopeia (U.S.P.) Units/tablet on a daily basis.

10. The method of claim 1, wherein the digestive enzymes further comprise a cellulase, a sucrase, or a maltase, either singularly or in any combination thereof.

11. The method of claim 1, wherein the method comprises administering an amount of digestive enzymes on a daily basis, wherein said amount is determined according to the age of the individual.

12. The method of claim 1, wherein the digestive enzymes comprise pancreatic enzymes.

13. The method of claim 1, wherein the protease comprises trypsin or chymotrypsin.

14. The method of claim 1, wherein the level of fecal chymotrypsin is measured by an enzymatic spectrophotometry method.

15. The method of claim 1, wherein administration of the digestive enzymes improves protein digestion.